On October 17, 2023, the clinical trial program of "Phase Ib/II Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ST-1898 Tablets in Patients with Non-surgically Resectable or Metastatic Melanoma" was successfully initiated at Beijing Cancer Hospital.

On March 14, 2023, Scitech Pharma announced that ST-1898 Tablets, the first AI discovered and designed anti-tumor targeted drug, completed dosing of the first subject in Phase Ib/II clinical trial at Beijing Cancer Hospital.

On February 13, 2023, the Phase I/IIa clinical trial of ST-1703 tablets in patients with HER2-positive advanced solid tumors (including brain metastases) was successfully initiated at Jiangsu Province Hospital.

The signing ceremony of the strategic cooperation between Scitech Pharma and Shanghai East Hospital was successfully held in Shanghai on December 18.

On September 10, 2021, Scitech Pharma ST-1703 clinical trial application was approved by the National Medical Products Administration (NMPA) (notification number: 2021LP01474, 2021LP01475). This is another project of Scitech Pharmaceuticals entering the clinical study stage after ST-1898 was launched in clinical trial in 2020. The clinical phase I trial will be formally launched at Shanghai East Hospital very soon, with Professor Guo Ye as the principal investigator.

On July 8, 2020, Scitech Pharmaceutical received the Notice of Drug Clinical Trial Approval from the National Medical Products Administration (NMPA), which approved ST-1898 to conduct clinical trials for solid tumor indications.

The clinical trial application of ST-1898, a class 1 small molecule drug with global independent intellectual property rights was officially accepted by NMPA on May 8, 2020.

Dr. Wang Yuan, Chairman of 2Y-Chem, Ltd. visited Scitech Pharmaceuticals, and Dr. Wang gave a detailed explanation on the key elements in the development of new chemical drugs.